List Title | APhA DrugInfoLine

Oncology

SORT BY: Most Recent Most Viewed

April 16, 2019

VTE prophylaxis for high-risk ambulatory patients with cancer

READ

PREVIEW
Use of apixaban (Eliquis—Bristol-Myers Squibb, Pfizer) as thromboprophylaxis in intermediate- to high-risk ambulatory patients receiving chemotherapy for various types of cancers reduced the risk...
February 26, 2019

Another negative trial for vitamin D supplementation

READ

PREVIEW
Supplementation with high-dose vitamin D in older adults did not lower the incidence of invasive cancer or adverse cardiovascular (CV) events compared with placebo, according to results of the...
February 5, 2019

Treatment outcomes improved in nonmetastatic pancreatic cancer

READ

PREVIEW
In patients with nonmetastatic resected pancreatic adenocarcinoma, adjuvant chemotherapy with a modified FOLFIRINOX regimen led to significantly longer survival than treatment with gemcitabine (...
September 18, 2018

Complementary medicines associated with poor outcomes in patients with cancer

READ

PREVIEW
Patients with cancer who used complementary medicines had higher refusal rates of surgery, chemotherapy, radiotherapy, and hormone therapy compared with those who did not use these alternative...
August 28, 2018

Practice-changing data for nonmetastatic, castrate-resistant prostate cancer

READ

PREVIEW
Two trials published in the New England Journal of Medicine showed that use of the next-generation androgen-receptor blockers apalutamide (Erleada—Janssen) or enzalutamide (Xtandi—...

Pages

Medication Monitor

RSS Follow Medication Monitor on Twitter Follow APhA Druginfoline on Twitter

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.